KF
Therapeutic Areas
Kura Oncology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Tipifarnib | HRAS-mutant Head & Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 |
| Ziftomenib (KO-539) | NPM1-mutant Acute Myeloid Leukemia (AML) | Phase 1/2 |
| KO-2806 | Advanced Solid Tumors (Combination Therapy) | Phase 1 |
Leadership Team at Kura Oncology
TW
Troy Wilson, Ph.D., J.D.
President & Chief Executive Officer
TB
Teresa Bair, J.D.
Chief Legal Officer
FB
Francis Burrows, Ph.D.
Chief Scientific Officer
ML
Mollie Leoni, M.D.
Chief Medical Officer
BP
Brian Powl
Chief Commercial Officer
RB
Roger Bakale, Ph.D.
Senior Vice President, Manufacturing and Supply Chain
TD
Tom Doyle
Senior Vice President, Finance & Accounting
SV
Samir Vattompadam
Senior Vice President, Global Program Leadership